

The oncoprotein HBXIP – its functions and roles in oncogenesis

Grudzinska M.^{1,A-D}, Lomperta K.^{1,2,C}, Jakubowska K.^{2,C}, Samocik P.^{3,B,C,E}, Jarzabek K.^{4,E}, Kanczuga-Koda L.^{2,C,E}, Wincewicz A.^{5,E}, Koda M.^{1,C,E,F}

1. Department of General Pathomorphology, Medical University of Białystok, Białystok, Poland
2. Department of Pathology, Maria Skłodowska-Curie Memorial Białystok Oncology Center, Białystok, Poland
3. Department of Urology, J. Sniadecki Provincial Hospital of Białystok, Białystok, Poland.
4. Department of Reproduction and Gynecological Endocrinology, Medical University of Białystok, Białystok, Poland
5. Non Public Health Care Unit - Department of Pathology, Kielce, Poland

A - Conception and study design; **B** - Collection of data; **C** - Data analysis; **D** - Writing the paper; **E** - Review article; **F** - Approval of the final version of the article; **G** - Other (please specify)

ABSTRACT

Nowadays, Hepatitis B X interacting protein (HBXIP) is an object of scientists' interest worldwide. It is a protein with significant involvement in the development of malignant tumors like breast or ovarian cancer. One of the most important functions of HBXIP is the regulation of cell proliferation, which is related to the progression of a cell cycle. Many studies provide the growing number of evidence that HBXIP plays various important roles, including the regulation of a cell cycle through complexes with survivin, belonging to the inhibitors of apoptosis and interactions with transcriptional factors like STAT4, SP1, TFIID or E2F1. It also has the influence on the promotion of tumor angiogenesis thanks to the association with VEGF and FGF8. Another important role of HBXIP is a reprogramming of glucose metabolism to conditions favorable to growing cancerous cells due

to regulating the activation of SCO2 and PDHA1. Furthermore, it impacts on the complement-dependent cytotoxicity, also, HBXIP affects on lipid metabolism through disturbing of metabolic pathways of FAS. According to recent studies, HBXIP can be used as a prognostic biomarker in many tumors, including cervical cancer, ovarian cancer, and esophageal squamous cell carcinoma thanks to the high expression of this protein noted exclusively in these tumor tissues. What is even more interesting, it significantly correlates with clinical attributes like metastasis to lymph nodes or grading and in some cases can potentially be used as the indicator of prognosis of treatment effectiveness. The paper is review through main functions of HBXIP and its possible applications.

Keywords: HBXIP, survivin, oncoprotein, transcription factor

DOI: 10.5604/01.3001.0012.8350

***Corresponding author:**

Malgorzata Grudzinska, Department of General Pathomorphology, Medical University of Białystok Białystok, Poland; e-mail: malg.grudzinska@gmail.com

Received: 25.10. 2018

Accepted: 23.12.2018

Progress in Health Sciences

Vol. 8(2) 2018 pp 215-222

© Medical University of Białystok, Poland

INTRODUCTION

Hepatitis B X-interacting protein (HBXIP) is a conserved 18-kDa protein, which was primarily identified in liver cells because of its interaction with hepatitis B virus X protein [1]. Further studies have shown that expression of HBXIP does not restrict exclusively to liver, but also to majority of other tissues [2]. Currently scientists try to explain the role of HBXIP in process of carcinogenesis and determine the value of HBXIP as a prognostic or predictive marker. Additional interesting aspects of this protein are studies that have proven linkage between high expression of HBXIP and development of the malignant tumors like breast or ovarian cancer. HBXIP is commonly named as the oncoprotein controlling growth and migration of cells. Moreover, it regulates cell proliferation, which is related with progression of the cell cycle [3,4].

HBXIP and survivin

Survivin is the smallest member of the inhibitors of apoptosis (IAP), family of proteins, involved in the inhibition of apoptosis and regulation of a cell cycle [5]. Survivin, despite the fact being discovered two decades ago, still remains in the scope of scientific interest. It is linked with various divergent functions, which it performs. In a normal cell it has an impact on proliferation and participates in regulation of a cell cycle. On the other hand, in cancer cells survivin is up-regulated and contributes to regulation of apoptosis. In recent years studies have shown the fact that HBXIP is a co-factor of survivin during restraining of apoptosis in cancerous cells [5,6]. Marusawa et al. described correlation between survivin and HBXIP. It has been proven that the relation between those proteins is an essential condition to reveal antiapoptotic properties of survivin [7]. There is a speculation that HBXIP-survivin complex prohibits composition of apoptosome. Thanks to binding this complex with Apaf-1 it becomes impossible to activate procaspase-9, because it selectively suppresses initiation of apoptosis [7,8]. Lack of expression of HBXIP or survivin yields possibility of cells to execute apoptosis [9].

HBXIP as a coactivator of transcriptional factors

Nowadays HBXIP is defined as oncoprotein having large importance in developing of breast cancer. HBXIP can serve as a coactivator for various transcription factors such as STAT4, SP1, TFIID or E2F1. The nuclear function of HBXIP is an contributing impact on phosphorylation of both HBXIP and c-Fos [10].

Liu et al. proved the influence of HBXIP on the promoting growth and migration of breast cancer through the influence of that protein on

STAT4. The interaction of HBXIP with a signal transducer and an activator of transcription 4 (STAT4) up-regulates S100A4 [11]. The intensified expression of S100A4 has an effect on the growth of breast cancer. Other studies have shown a strict correlation between S100A4 protein and progression and metastasis of tumors on various organs, such as esophagus, thyroid gland, large intestine, pancreas or prostate [12-15]. HBXIP has an impact on the reduction of PTEN protein's expression. The lowering of the level of PTEN is possible thanks to the elevation of the expression of DNMT1 protein and hypermethylation of promotor PTEN. Decreased expression of PTEN leads to higher expression of Akt protein (signal transduction PTEN/PI3K/AKT), which may lead to the increase of S100A4 and the growth of breast cancer [16].

Yue et al. reports that HBXIP is a oncoprotein due to the activation of transcriptional regulatory protein LIM-only protein 4 (LMO4) via Sp1 [17]. LMO4 is transcription regulator having an effect on the progression of a cell cycle, indirectly increases the quantity of cyclin C and cyclin D [18,19]. It has been shown that there is an overexpression of LMO4 in breast cancer and squamous cell oral carcinoma. Moreover, a higher expression correlates with worse prognosis [20-22]. Transcript factor Sp1 (specificity protein 1) plays an important role in the interaction between HBXIP and LMO4. This binding factor Sp1 and HBXIP leads to the activation of LMO4 promotor. The consequence of that process is the increased expression of LMO4, which has an important role in the development of breast cancer. Thus, Yue et al. suggest the major role of HBXIP in tumor progression [17].

Furthermore, HBXIP increases proliferation of breast cancer cells co-activator of transcription factor II D (TFIID) [23]. TFIID is one part of composing the RNA polymerase pre-initiation complex. It is bound with TATA box in order to begin transcription. The connection of HBXIP and TFIID results in the activation of promotor Lin28B. It has been reported that Lin28B acts as a oncogene promoting proliferation of cancer cells. It blocks selectively miR-let-7 [24-27]. Liu et al. speculate about the cooperation of oncogenes HBXIP and Lin28B, which leads to a stimulation of tumor cells growth. Furthermore, these authors suggest influence of Lin28 on high level of HBXIP [23].

Skp2 (S-phase kinase-associated protein 2) is a member of the F-box family that plays a crucial role in the coordination of a cell cycle [28,29]. It was noted, that Skp2 can suppress apoptosis through p53 [30]. Skp2 is being considered as an oncogenic protein because of its involvement in the mechanism of degradation of the cyclin-dependent

kinase (CDK) inhibitor p27(Kip1) [31]. According to the latest research Skp2 expression is correlated with HBXIP expression. Skp2 is one of the factors, that are responsible for the migration of the ovarian cancer cells [32]. Xu F et al. suggest that HBXIP mediates in this process through the interaction with transcriptional factor Sp1, what makes connection with promotor Skp2 possible [33]. Furthermore, HBXIP can influence on Skp2 expression through E2F1 [34]. E2F1 is the transcriptional factor, which belongs to the family E2F taking part in a cell cycle control [35]. Promotor Skp2 contains active site for E2F1. Binding E2F1 factor with HBXIP yields the activation of Skp2's promotor. [34]. The reports suggest an active input of HBXIP in promoting of cancer cells migration. Thus, HBXIP is regarded as an essential co-activator of transcriptional factors in cancerous cells.

Correlation with angiogenesis in tumors

Angiogenesis is a formation of new vascular channels (e.g. capillaries) from preexisting ones and may occur as a part of pathological process during the development of malignant tumor [36]. In microenvironment of tumor multiple signal particles with an impact on angiogenesis can be found. Malignant cells have an ability to release the growth factors and cytokines activating various signal pathways leading to creation of the new blood vessels [37]. Important growth factors connected with angiogenesis are agents from sub-families FGF and VEGF [38,39]. The level of expression of FGF8 have been tested in tissues with confirmed breast cancer. Those studies have proven the correlation between FGF8 and HBXIP. Moreover, inhibition of expression HBXIP reduced level of FGF8. That fact suggests the influence of HBXIP on activity of FGF8 promotor [40]. The Vascular endothelial growth factor (VEGF) is a modulator of angiogenesis, it stimulates mitosis and migration of endothelium cells. Its high expression is connected with bad prognosis during the treatment of breast cancer [39,41]. Wang et al. reported that HBXIP does not have an impact on the activity and the expression of VEGF in hepatoma cells. The increased intensity of angiogenesis in hepatoma is rather considered with the increased activation of eNOS signaling pathway [42]. On the other hand, Liu et al. proved that HBXIP increases the level of VEGF in breast cancer cells through suppression of miRNA-503 [40]. It has been suggested that HBXIP increases expression both of FGF8 and VEGF, which promotes angiogenesis in tumor environment.

Role of HBXIP in glucose metabolism

The glucose metabolism reprogramming is a necessary element of a growing cancerous cell.

Tumor tends to favor metabolism through anaerobic glycolysis rather than oxidative phosphorylation pathway. Among others, synthesis of cytochrome c oxidase 2 (SCO2) participates in the process of a modulation of the balance between the utilization of respiratory and glycolytic pathways [43]. Disruption of SCO2 in cancer cell results in switching the metabolic balance from oxidative phosphorylation to glycolysis. Fabao Liu et al. proved that a higher activity of HBXIP increased the level of intracellular glucose and lactase through downregulating SCO2 and PDHA1 in breast cancer cells. PDH E1 alpha (PDHA1) is a subunit of pyruvate dehydrogenase (PDH) complex, which provides the connection between glycolysis and the tricarboxylic acid cycle. PDHA1 knockdown enhances glucose intake, elevates the rate of glycolysis and lactate production. Hence influence of HBXIP on the glucose metabolism favors cancer cell to grow and proliferate [44]. Recently published paper suggests that HBXIP may depress gluconeogenesis. The suppression of PCK1 (Phosphoenolpyruvate carboxykinase 1), main enzyme of gluconeogenesis through HBXIP promotes hepatocarcinogenesis [45]. Reprogramming of a metabolism of glucose via HBXIP seems to be an important part of carcinogenesis.

Influence on aberration of lipid metabolism

Dysfunctional metabolism of lipids is a characteristic attribute of a growing tumor. The activity of some oncogenes or hypoxia can become the root of changes in lipid biosynthesis [46]. Cancer cells have the ability to reprogram metabolic pathways in order to survive [47]. FAS (fatty acid synthase) is an enzyme taking part in biosynthesis of fatty acids. High activity of FAS has been noticed in some types of cancerous cells. Moreover, high expression of *fasn* correlated with unfavorable prognosis [48,49]. The increased activity of FAS has been also noticed in precancerous state cells [50]. Zhao et al. researched the influence of HBXIP on abnormal metabolism of lipids during carcenogenesis. In their paper they tested the expression of HBXIP and FAS [51]. In breast cancer cells there was shown a correlation between FAS and HBXIP expression, whereas the decreased level of HBXIP expression in colon cancer cells had an effect on the lowering of FAS expression. The relationship between HBXIP and FAS is a consequence of SREBP-1c transcription factor activation. HBXIP has an ability to connect with LXR α/β , which has potential to induce some of the lipogenesis genes [52]. Right after the connection of HBXIP with LXR α/β it comes to activation of SREBP-1c promotor, which is responsible for the regulation of hepatic fatty acids synthesis. Zhao et al. proved the connection between the incorrect lipid metabolism and HBXIP,

which has the ability to activate LXR/SREBP-1c/FAS [51].

Role of HBXIP in Complement-dependent cytotoxicity (CDC)

Complement-dependent cytotoxicity (CDC) is one of the effector mechanisms of monoclonal antibodies. Bounding of the IgG or IgM antibodies with the cluster of designation on a cancerous cell activates classical pathway of the complement system. The result forms a membrane attack complex (MAC). As an effect it comes to lysis of a target cell [53]. Forming of MAC can be controlled through membrane proteins such as CD35, CD46, CD56, CD55, CD59, which are overexpressed in cancerous cells [54,55].

Cui et al. proved that HBXIP has a strong impact on CD46, CD55 and CD59 expression in cancer cells. Overexpression of HBXIP caused the increase of antigen expression. Moreover, the authors suggest that NF- κ B is responsible for upregulation of CD46, CD55 and CD59 [56].

The connection among regulation of CD59 expression and NF- κ B was researched also by Du et al. According to their paper, NF- κ B and CREB (as an enhancer-binding protein) have the influence on an induced expression of CD59 [57]. HBXIP contributes to the immune escape of a carcinoma cell from CDC by up-regulating the expression of CD46, CD55 and CD59.

HBXIP as a new prognostic tumor marker

Cervical cancer. Cervical cancer is one of the most common female tumors worldwide. Data from 2012 says about 528,000 new cases and 266,000 deaths due to this type of cancer in the world [58]. In the developing countries high mortality is connected with delayed diagnosis and high-level risk of metastasis [59,60].

It seems to be reasonable to identify new, specific biomarkers, with practical application, novel predictive indicators, in the case of cervical cancer as therapeutic targets. Li et al. tested the expression of HBXIP protein in cervical cancer and cervical intraepithelial neoplasia (CIN). HBXIP protein was not expressed in healthy cervical epithelium. On the other hand, HBXIP expression has been noticed in atypical cells: CIN, gland and epithelium from squamous cell carcinoma (SCC). High expression occurred only in atypical cells, not in regular neighbor cells. HBXIP was located mostly in cytoplasm. Moreover, its expression is correlated with clinical level and metastasis. It was also noted, that high expression of this protein is connected with lower overall survival (OS) [61].

Potentially, HBXIP may be the indicator of prognosis in the treatment effectiveness of cervical cancer. Tests suggest usefulness of HBXIP as a new diagnostic and prognostic marker in the

treatment of SCC. However, there is the need for complex analysis of molecular mechanisms in order to recognize an exact biological function of HBXIP in carcinogenesis.

Ovarian cancer. The morbidity rate of ovarian cancer is estimated on about 240,000 new cases and is cause of 150,000 deaths per year [62]. Ovarian cancer in over 75% of cases is diagnosed on advanced phase (III/IV stage). The disease diagnosis in advanced stage and difficulties in early diagnosis are main reasons of high mortality rate of this type of tumor [63]. Despite the improvement of treatment possibilities, prognosis still remains unsatisfying [64].

There were attempts of estimation of connection between HBXIP expression and ovarian cancer progression. Scientists demonstrated positive expression HBXIP in ovarian cancer tissue. In regular tissues its expression did not occur [33].

Wang et al. reported that overexpression of HBXIP is significantly correlated with clinical attribute like metastasis to lymph nodes or grading. That indicates that HBXIP can be used as a potential prognostic marker in ovarian cancer, however there is the necessity of running additional trials to verify those studies [65].

Esophageal squamous cell carcinoma (ESCC). Annually there are over 400,000 diagnosed cases of esophageal cancer [66]. Statistically, male patients suffer more frequently. Among the risk factors, the most common are smoking tobacco and drinking alcohol beverages [67,68].

Scientists tested the correlation between patients' clinical features with ESCC and the expression of HBXIP. In the tissue taken from the patients with z ESCC significantly higher level of HBXIP has been detected. The expression of this protein correlated with TNM stage, histological grade and lymph node metastasis [69].

That fact suggests the potential impact of HBXIP as oncoprotein in ESCC, however these results require further research.

CONCLUSIONS

This review of the functions and role of HBXIP in oncogenesis has been focused largely on data published for the recent few years. According to collected data the oncoprotein HBXIP has many important roles, such as the control of proliferation, growth and migration of cancerous cells. What is even more interesting, HBXIP has also many functions like activation of transcriptional factors, modulation of immune response, regulation of metabolism of glucose and lipids. It also acts as angiogenesis stimulator in cancer cell. Further research can bring thorough knowledge about involvement of HBXIP various processes, what could be useful to find a new role of this protein in

diagnostic or therapy. The question is the high number of the roles, which it plays in different processes, don't exclude this protein as potential therapeutic target. On the other hand, the association of HBXIP with numerous clinical attributes proclaims that this protein can be used as prognostic marker. In the light of the mentioned above facts it is reasonable to run further research to confirm the role of HBXIP as a significant biomarker of carcinogenesis.

Conflicts of interest

The authors declare that they have no conflicts of interest.

REFERENCES

1. Wen Y, Golubkov VS, Strongin AY, Jiang W, Reed JC. Interaction of Hepatitis B Viral Oncoprotein with Cellular Target HBXIP Dysregulates Centrosome Dynamics and Mitotic Spindle Formation. *J Biol Chem*. 2008 Feb 1;283(5):2793-803.
2. Fujii R, Zhu C, Wen Y, Marusawa H, Bailly-Maitre B, Matsuzawa S, Zhang H, Kim Y, Bennett CF, Jiang W, Reed JC. HBXIP, Cellular Target of Hepatitis B Virus Oncoprotein, Is a Regulator of Centrosome Dynamics and Cytokinesis. *Cancer Res*. 2006 Sep 15;66(18):9099-107.
3. Wang FZ, Sha L, Zhang WY, Wu LY, Qiao L, Li N, Zhang XD, Ye LH. Involvement of hepatitis B X-interacting protein (HBXIP) in proliferation regulation of cells. *Acta Pharmacol. Sin*. 2007 Mar;28(3):431-8.
4. Wang FZ, Sha L, Ye LH, Zhang XD. Promotion of cell proliferation by HBXIP via upregulation of human telomerase reverse transcriptase in human mesenchymal stem cells. *Acta Pharmacol. Sin*. 2008 Jan;29(1):83-9.
5. Li F, Role of survivin and its splice variants in tumorigenesis. *Br J Cancer* 2005 Jan 31;92(2): 212-6.
6. Chen WC, Liu Q, Fu JX, Kang SY. Expression of survivin and its significance in colorectal cancer. *World J Gastroenterol*. 2004 Oct 1;10(19):2886-9.
7. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC. HBXIP functions as a cofactor of survivin in apoptosis suppression. *EMBO J*. 2003 Jun 2;22(11):2729-40.
8. Ma J, Sun T, Park S, Shen G, Liu J. The role of hepatitis B virus X protein is related to its differential intracellular localization. *Acta Biochim Biophys Sin (Shanghai)*. 2011 Aug; 43(8):583-8.
9. Minczuk M, Mroczek S, Pawlak SD, Stępień PP. Human ATP-dependent RNA/DNA helicase hSuv3p interacts with the cofactor of survivin HBXIP. *FEBS J*. 2005 Oct;272(19):5008-19.
10. Zhang G, Li M, Jin J, Bai Y, Yang C. Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. *Asian Pac J Cancer Prev*. 2011;12(8):2075-80.
11. Liu S, Li L, Zhang Y, Zhang Y, Zhao Y, You X, Lin Z, Zhang X, Ye L. The Oncoprotein HBXIP Uses Two Pathways to Up-regulate S100A4 in Promotion of Growth and Migration of Breast Cancer Cells. *J Biol Chem*. 2012 Aug 31;287(36):30228-39.
12. Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-Shaw S, Spiegelman VS, Setaluri V, Mukhtar H. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. *Proc Natl Acad Sci USA*. 2006 Oct 3;103(40):14825-30. Epub 2006 Sep 21.
13. Cabezon T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, Rank F, Myklebust JH, Maelandsmo GM, Lukanidin E, Ambartsumian N. Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. *Int. J. Cancer* 2007 Oct 1;121:1433-44.
14. Malashkevich VN, Varney KM, Garrett SC, Wilder PT, Knight D, Charpentier TH, Ramagopal UA, Almo SC, Weber DJ, Bresnick AR. Structure of Ca²⁺-bound S100A4 and its interaction with peptides derived from nonmuscle myosin-IIA. *Biochemistry* 2008 May 6;47(18):5111-26.
15. Ismail NI, Kaur G, Hashim H, Hassan MS. S100A4 overexpression proves to be independent marker for breast cancer progression. *Cancer Cell Int*. 2008;8:12-18.
16. Liu S, Li L, Zhang Y, Zhang Y, Zhao Y, You X, Lin Z, Zhang X, Ye L. The Oncoprotein HBXIP Uses Two Pathways to Up-regulate S100A4 in Promotion of Growth and Migration of Breast Cancer Cells. *J Biol Chem* 2012 Aug 31;287(36):30228-39.
17. Yue L, Li L, Liu F, Hu N, Zhang W, Bai X, Li Y, Zhang Y, Fu L, Zhang X, Ye L. The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells. *Carcinogenesis* 2013 Apr;34(4):927-35.
18. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK 3rd, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin D1 is required for transformation by activated Neu and is induced

- through an E2F-dependent signaling pathway. *Mol. Cell. Biol.* 2000 Jan;20:672–83.
19. Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. *Oncogene* 2009 Oct 15;28(41): 3608–18.
 20. Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G, Kallioniemi OP. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. *Cancer Res* 2002 Mar 1;62(5):1256–60.
 21. Wang N, Lin KK, Lu Z, Lam KS, Newton R, Xu X, Yu Z, Gill GN, Andersen B. The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells. *Oncogene* 2007 Sep 27;26(44):6431–41.
 22. Tian Y, Wang N, Lu Z. Repression of Lim only protein 4-activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells. *Clin. Exp. Meta-stasis* 2010 Oct;27(7): 455–63.
 23. Liu Q, Bai X, Li H. The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells. *Int J Cancer* 2013;133:1310–22.
 24. Piskounova E, Polyarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D, Gregory RI. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. *Cell* 2011;147:1066–79.
 25. Leppert U, Henke W, Huang X, Müller JM, Dubiel W. Post-transcriptional fine-tuning of COP9 signalosome subunit biosynthesis is regulated by the c-Myc/Lin28B/let-7 pathway. *J Mol Biol* 2011 Jun 24;409:710–21.
 26. Viswanathan SR, Daley GQ. Lin28: A microRNA regulator with a macro role. *Cell* 2010 Feb 19;140:445–9.
 27. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. *Cell*. 2009 Nov 13;139(4):693–706.
 28. Zhang H, Kobayashi R, Galaktionov K and Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. *Cell*. 1995 Sep 22;82:915–25.
 29. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. *Nat Med* 1997 Feb;3(2):227–30.
 30. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. *Cancer Sci.* 2009 Aug;100(8):1374–81.
 31. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. *Cancer*. 2008 Apr 1;112(7):1415–24.
 32. Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P and Pandolfi PP. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. *Nat Cell Biol* 2009 Apr;11(4):420–32.
 33. Xu F, Zhu X, Han T, You X, Liu F, Ye L, Zhang X, Wang X, Yao Y. The onco-protein hepatitis B X-interacting protein promotes the migration of ovarian cancer cells through the upregulation of S-phase kinase-associated protein 2 by Sp1. *Int J Oncol* 2014 Jul;45(1): 255–63.
 34. Xu F, You X, Liu F, Shen X, Yao Y, Ye L, Zhang X. The oncoprotein HBXIP upregulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells. *Cancer Lett.* 2013 Jun 1;333(1):124–32.
 35. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. *Eur J Cancer*. 2005 Nov;41(16):2403–14.
 36. Kinja K, Rohit S, Mandloi A, Sharma I, Savita S. Anti-angiogenic therapy - past, present and future. *Rec Res Sci Tech* 2011 3:8–15.
 37. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. *Nat Med*. 2011 Nov 7;17(11):1359–70.
 38. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer*. 2010 Feb;10(2):116–29.
 39. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. *Ann Oncol.* 2009 Oct;20(10):1639–46.
 40. Liu, F, You, X, Wang, Y, Liu Q, Liu Y, Zhang S, Chen L, Zhang X, Ye L. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. *Carcinogenesis* 2014 May;35(5):1144–53.
 41. Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, Dewhirst MW. β -arrestin1 mediates metastatic growth of breast cancer cells by

- facilitating HIF-1-dependent VEGF expression. *Oncogene*. 2012 Jan 19;31(3):282-92.
42. Wang F, Fei H, Qi B, Yao S, Chang Z. Overexpression of hepatitis B x-interacting protein in HepG2 cells enhances tumor-induced angiogenesis. *Mol Cell Biochem* 2012 May;364(1-2):165-71
43. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. *NatRevCancer*. 2011 Feb;11(2):85-95.
44. Liu F, Zhang W, You X, Liu Y, Li Y, Wang Z, Wang Y, Zhang X, Ye L. The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer. *Oncotarget*. 2015 Sep 29;6(29):27199-213.
45. Shi H, Fang R, Li Y, Li L, Zhang W, Wang H, Chen F, Zhang S, Zhang X, Ye L. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells. *Cancer Lett* 2016 Nov 28;382(2):147-56.
46. Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. *World J Gastroenterol* 2014 Mar 7;20(9):2279-303.
47. Garrido P, Osorio FG, Morán J, Cabello E, Alonso A, Freije JM, González C. Loss of GLUT4 induces metabolic reprogramming and impairs viability of breast cancer cells. *J Cell Physiol* 2015 Jan;230(1):191-8.
48. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. *J Clin Oncol* 2008 26: 5713-20.
49. Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G, Alo PL. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. *Anticancer Res*. 2004 Nov-Dec;24(6):4169-73.
50. Kusakabe T, Nashimoto A, Honma K, Suzuki T. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. *Histopathology* 2002 Jan;40(1):71-9.
51. Zhao Y, Li H, Zhang Y, Li L, Fang R, Li Y, Liu Q, Zhang W, Qiu L, Liu F, Zhang X, Ye L. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade. *Cancer Res*. 2016 Aug 15;76(16):4696-707.
52. Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism *J Endocrinol* 2010 Mar;204(3):233-40.
53. Presta LG. Molecular engineering and design of therapeutic antibodies. *Curr. Opin. Immunol* 2008 Aug;20(4):460-70.
54. Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. *Hematol Oncol Clin North Am* 2006;20:585-612.
55. Zhang S, Shan C, Cui W, You X, Du Y, Kong G, Gao F, Ye L, Zhang X. Hepatitis B virus X protein protects hepatoma and hepatic cells from complement-dependent cytotoxicity by up-regulation of CD46 *FEBS Lett*. 2013 Mar 18; 587(6):645-51.
56. Cui W, Zhao Y, Shan C, Kong G, Hu N, Zhang Y, Zhang S, Zhang W, Zhang Y, Zhang X, Ye L. HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF- κ B signaling to protect breast cancer cells from complement attack. *FEBS Lett* 2012 Mar 23;586(6):766-71.
57. Du Y, Teng X, Wang N, Zhang X, Chen J, Ding P, Qiao Q, Wang Q, Zhang L, Yang C, Yang Z, Chu Y, Du X, Zhou X, Hu W. NF- κ B and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. *J Biol Chem*. 2014 Jan 31;289(5): 2711-24.
58. GLOBOCAN 2012 v1.0. Cervical Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. [Internet] Available from: http://globocan.iarc.fr/Pa-ges/fact_sheets_cancer.aspx.
59. Liu SY, Zheng PS. High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer. *Oncotarget* 2013 Dec;4(12):2462-75.
60. Pfaendler KS, Wenzel L, Mechanic MB, Penner KR. Cervical cancer survivorship: long-term quality of life and social support. *Clin Ther* 2015 Jan 1;37(1):39-48.
61. Li N, Wang Y, Che S, Yang Y, Piao J, Liu S, Lin Z. HBXIP over expression as an independent biomarker for cervical cancer. *Exp Mol Pathol*. 2017 Feb;102(1):133-7.
62. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015 Mar;65(2):87-108.
63. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. *J Oncol*. 2010;2010:932371
64. Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. *J Natl Cancer Inst*. 2015 Jan 27;107(2)
65. Wang Y, Sun J, Li N, Che S, Jin T, Liu S, Lin Z. HBXIP overexpression is correlated with the clinical features and survival outcome of

- ovarian cancer. *J Ovarian Res.* 2017 Apr 7; 10(1):26.
66. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. *Eur J Cancer.* 2009 Mar;45(5):756-64.
67. Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC; Australian Cancer Study. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. *Gastroenterology* 2009 Apr; 136(4):1215-24.
68. Pandeya N, Williams GM, Sadhegi S, Green AC, Webb PM, Whiteman DC. Associations of duration, intensity, and quantity of smoking with adenocarcinoma and squamous cell carcinoma of the esophagus. *Am J Epidemiol* 2008 Jul 1;168(1):105-14.
69. Xia H, Ma L, Li J, Bai H, Wang D. Elevated HBXIP expression is associated with aggressive phenotype and poor prognosis in esophageal squamous cell carcinoma. *Am J Cancer Res* 2017 Nov 1;7(11):2190-8.